Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

News Releases

12 Nov '21
Retrospective medical chart review studies show outcomes based on disease severity and highlight unmet treatment needs in people with HRS-1 DUBLIN , Nov. 12, 2021 /PRNewswire/ -- Mallinckrodt plc , (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced findings from two retrospective
28 Oct '21
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN, Ireland and LAKEWOOD, Colo. USA – October 28, 2021 –  Mallinckrodt plc  (OTCMKTS: MNKKQ), a
25 Oct '21
U.K., multicenter, retrospective medical chart review study showed terlipressin is commonly prescribed for esophageal variceal hemorrhage (EVH) in real world clinical practice DUBLIN , Oct. 25, 2021 /PRNewswire/ --  Mallinckrodt plc , (OTCMKTS: MNKKQ) a global biopharmaceutical company, today

Recent Events

Featured Reports

go back to the top of the page